- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07595770
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ANCRE)
13 mai 2026 mis à jour par: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Study on the Safety and Efficacy of Adalimumab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
Aperçu de l'étude
Statut
Recrutement
Les conditions
Intervention / Traitement
Description détaillée
CROSS Study showed that the pathological complete response (pCR) rate of patients with esophageal cancer (23% of whom were esophageal squamous cell carcinoma, ESCC) after neoadjuvant radiotherapy and chemotherapy was 29%.
NEOCRTEC5010 Study showed that the pCR rate was 43.2% in locally advanced esophageal squamous cell carcinoma, which means that more than half of patients still cannot achieve ideal therapeutic effects from existing treatment options.
In addition, the recurrence rate after surgical resection compromises the long-term survival rate of patients.
Therefore, exploring new treatment strategies to improve the treatment efficacy and survival rate of esophageal cancer patients has important clinical significance.
Currently, the significance of immunotherapy combined with chemoradiotherapy in terms of pathological complete response (pCR) rates and postoperative survival quality for locally advanced esophageal squamous cell carcinoma remains unclear.
Therefore, this study aims to systematically evaluate the safety and efficacy of adebrelimab in combination with paclitaxel, carboplatin, and short-course radiotherapy as neoadjuvant therapy for ESCC.
By integrating immunotherapy with existing standard treatment regimens, this study seeks to significantly improve pCR rates, optimize surgical resection outcomes, ultimately prolong disease-free survival (DFS), and enhance overall survival (OS).
The implementation of this study is expected to provide innovative approaches and methods for the clinical treatment of ESCC, holding important clinical application value and significance.
Type d'étude
Interventionnel
Inscription (Estimé)
37
Phase
- Phase 2
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Baisheng Chen, M.D, PhD
- Numéro de téléphone: +86-13560471611
- E-mail: Pason06213367@163.com
Lieux d'étude
-
-
Guangdong
-
Guangzhou, Guangdong, Chine
- Recrutement
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Contact:
- Baisheng Chen Chen
- Numéro de téléphone: +86-13560471611
- E-mail: Pason06213367@163.com
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- - 1. Provided informed consent and sign the informed consent form;
- 2. Male or female, Aged 18-75 years (counted on the date of signing informed consent);
- 3. Pathological confirmed ESCC;
- 4. Patients assessed by thoracic oncologists as resectable without distant metastasis
- 5. Patients evaluate with clinical staging of T1-4aN1-3M0 or T3-4aN0M0(AJCC 9.0) based on imaging and pathological examination results;
- 6. Have at least one assessable lesion according to the RECIST V1.1
- 7. ECOG-PS score: 0-1;
- 8. Patients with normal function of organs such as heart, brain, lungs, and kidneys who can tolerate surgery;
- 9. With a life expectancy of ≥ 6 weeks;
- 10. Adequate major organ function without severe hematologic, cardiac, pulmonary, hepatic, renal, or bone marrow dysfunction, and no immunodeficiency disease;
Exclusion Criteria:
- 1. Patients who have received or are currently receiving chemotherapy, radiotherapy, immunotherapy, or targeted therapy
- 2. Patients with distant metastasis or inability to undergo resection after evaluation by thoracic surgeons
- 3. Simultaneously developing tumors in other parts of the body
- 4. Severe impairment of heart, liver, and kidney function (heart function grade 3-4, ALT and/or AST exceeding the upper limit of normal by more than 1.5 times, Cr (serum creatinine) exceeding the upper limit of normal by more than 1.5 times)
- 5. Patients with a history of autoimmune diseases who were receiving immunosuppressive therapy prior to enrollment, with immunosuppressive doses>10 mg/day or oral prednisone for more than 2 weeks
- 6. Severe allergy to immune preparations
- 7. Abnormal coagulation function: (PT>16s, APTT>53s, TT>21s, Fib<1.5 g/L), bleeding tendency or during thrombolytic or anticoagulant therapy
- 8. Pregnancy or lactation period
- 9. Other situations as judged by investigators not suitable for inclusion.;
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Adebrelimab and nab-paclitaxel plus carboplatin followed by radiotherapy
Patients would receive Adebrelimab (IV 1200mg d1) and nab-paclitaxel (IV 220 mg/m²d1) plus carboplatin (AUC = 5, d1) for two 21-day cycles, followed by one week off for radiotherapy (2.5 ⨉12 Gy).
After radiotherapy, another cycle of Adebrelimab (IV 1200mg d1) would be given.
4 to 6 weeks after completing the neoadjuvant therapy, patients would undergo esophagectomy.
|
Patients would receive Adebrelimab (IV 1200mg d1) and nab-paclitaxel (IV 220 mg/m²d1) plus carboplatin (AUC = 5, d1) for two 21-day cycles, followed by one week off for radiotherapy (2.5 ⨉12 Gy).
After radiotherapy, another cycle of Adebrelimab (IV 1200mg d1) would be given.
4 to 6 weeks after completing the neoadjuvant therapy, patients would undergo esophagectomy.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pathological complete response (pCR)
Délai: From patient enrollment to the end of surgery
|
The proportion of subjects with no residual viable tumor cells(ypT0N0) in the primary tumor and lymph nodes; that is, the proportion of patients who have achieved complete remission among PPS(Per-Protocol Set).
|
From patient enrollment to the end of surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
R0 resection rate
Délai: From patient enrollment to the end of surgery
|
The proportion of patients with tumor margins showing no residual cancer cells under the microscope after surgical resection.
That is, the proportion of patients in PPS achieving R0 resection.
|
From patient enrollment to the end of surgery
|
|
Disease free survival (DFS)
Délai: up to 24 months post-surgery
|
Disease free survival (DFS) refers to the time from the start of treatment until disease recurrence or death from any cause, whichever occurs first.
|
up to 24 months post-surgery
|
|
Overall survival (OS)
Délai: up to 24 months after surgery
|
OS is the time interval from the start of treatment to death due to any reason or loss of follow-up
|
up to 24 months after surgery
|
|
Major pathological remission (MPR)
Délai: From patient enrollment to the end of surgery
|
Major pathological remission (MPR) refers to the percentage of residual tumor cells in the tumor bed after neoadjuvant therapy being ≤ 10%, regardless of whether there are residual tumor cells in the lymph nodes.
|
From patient enrollment to the end of surgery
|
|
Progression free survival (PFS)
Délai: Up to 24 months post-surgery
|
PFS is defined as the time from the start of treatment to the date of first documentation of disease progression, or date of death, whichever occurred first.
|
Up to 24 months post-surgery
|
|
Event free survival (EFS)
Délai: From patient enrollment to the end of surgery
|
EFS refers to the time from the start of treatment to the occurrence of any event, including disease progression, cessation of treatment for any reason, or death.
|
From patient enrollment to the end of surgery
|
|
Adverse Events
Délai: from the first drug administration to within 30 days for the last Adebrelimab dose
|
Number of adverse events.
The evaluation criteria for adverse reactions are based on the American Cancer Institute Common Adverse Event Terminology 4.0 (CTCAE 5.0) and the Acute Radiation Injury Grading Standards of the American Oncology Radiotherapy Collaboration Group (RTOG).
|
from the first drug administration to within 30 days for the last Adebrelimab dose
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Collaborateurs
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
22 mai 2026
Achèvement primaire (Estimé)
1 janvier 2028
Achèvement de l'étude (Estimé)
1 octobre 2029
Dates d'inscription aux études
Première soumission
13 mai 2026
Première soumission répondant aux critères de contrôle qualité
13 mai 2026
Première publication (Réel)
19 mai 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
19 mai 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
13 mai 2026
Dernière vérification
1 mai 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Tumeurs par type histologique
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Tumeurs de la tête et du cou
- Tumeurs, glandulaires et épithéliales
- Maladies de l'oesophage
- Carcinome
- Tumeurs à cellules squameuses
- Carcinome épidermoïde
- Tumeurs de l'oesophage
- Carcinome épidermoïde de l'œsophage
- Produits chimiques organiques
- Thérapeutique
- Complexes de coordination
- Carboplatine
- Radiothérapie
- Paclitaxel lié à l'albumine de 130 nm
Autres numéros d'identification d'étude
- SYSKY-2025-799-02
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .